27 results
8-K
EX-99.1
IMPL
Impel Pharmaceuticals Inc
20 Dec 23
Impel Pharmaceuticals Announces Filing Voluntary Chapter 11 Cases and Signing of “Stalking Horse” Agreement to Facilitate Sale
6:08am
such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does
424B5
IMPL
Impel Pharmaceuticals Inc
5 Oct 23
Prospectus supplement for primary offering
5:19pm
and revenue targets. We do not intend to fill these vacated positions for the foreseeable future and, as a result, retaining our current sales personnel
8-K
EX-99.1
IMPL
Impel Pharmaceuticals Inc
18 Sep 23
Regulation FD Disclosure
9:53pm
Rep Targets 90 Rep Targets # HCPs ~8k ~11k % NEUROS (77%) (59%) % PCPs (13%) (26%) MARKET VOLUME TRX & % OVERALL MARKET 8.2M (35%) 9.3M (40%) BRANDED
PRE 14A
djvx i0i5
14 Apr 23
Preliminary proxy
4:11pm
8-K
EX-99.1
2gcldso
15 Aug 22
Impel PHARMACEUTICALS Announces SECOND Quarter 2022 Financial Results and Provides CORPORATE Update
8:06am
DEF 14A
g1ge4np
26 Apr 22
Definitive proxy
4:16pm
8-K
EX-99.1
sx7hzdxitqo5an7
14 Apr 22
Regulation FD Disclosure
8:30am
10-K
v1ybj0fk o4kj3oc
29 Mar 22
Annual report
5:09pm
8-K
EX-99.1
eeh pqxd7e9
18 Jan 22
Impel NeuroPharma Provides Updates on TrudhesaTM Launch
8:01am
8-K
EX-99.2
5kq kbv5nchwn
18 Jan 22
Impel NeuroPharma Provides Updates on TrudhesaTM Launch
8:01am
424B4
yft3j58t
10 Sep 21
Prospectus supplement with pricing info
4:01pm
DRS
ovmkq4qbv1
25 Aug 21
Draft registration statement
12:00am